These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 9624043)
21. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Wei XX; Chan S; Kwek S; Lewis J; Dao V; Zhang L; Cooperberg MR; Ryan CJ; Lin AM; Friedlander TW; Rini B; Kane C; Simko JP; Carroll PR; Small EJ; Fong L Cancer Immunol Res; 2016 Nov; 4(11):948-958. PubMed ID: 27688020 [TBL] [Abstract][Full Text] [Related]
22. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748 [TBL] [Abstract][Full Text] [Related]
23. Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI). Wank R; Song X; Gu S; Laumbacher B Immunotherapy; 2014; 6(3):269-82. PubMed ID: 24762072 [TBL] [Abstract][Full Text] [Related]
24. [Cell therapy for renal cell carcinoma]. Kawai K Gan To Kagaku Ryoho; 2002 Oct; 29(10):1745-51. PubMed ID: 12402424 [TBL] [Abstract][Full Text] [Related]
25. Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. Hussain M; Javeed A; Ashraf M; Al-Zaubai N; Stewart A; Mukhtar MM Pharmacol Res; 2012 Jul; 66(1):7-18. PubMed ID: 22449788 [TBL] [Abstract][Full Text] [Related]
26. Immunostimulants for malignant gliomas. Butowski N Neurosurg Clin N Am; 2010 Jan; 21(1):53-65. PubMed ID: 19944966 [TBL] [Abstract][Full Text] [Related]
27. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy. Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961 [TBL] [Abstract][Full Text] [Related]
28. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related]
30. Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha. Della Bella S; Nicola S; Riva A; Biasin M; Clerici M; Villa ML J Leukoc Biol; 2004 Jan; 75(1):106-16. PubMed ID: 14525963 [TBL] [Abstract][Full Text] [Related]
31. Interleukin 2 in cancer therapy. Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501 [TBL] [Abstract][Full Text] [Related]
32. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Atzpodien J; Kirchner H Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894 [TBL] [Abstract][Full Text] [Related]
33. Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use. Coronel A; Boyer A; Franssen JD; Romet-Lemonne JL; Fridman WH; Teillaud JL Br J Haematol; 2001 Sep; 114(3):671-80. PubMed ID: 11552997 [TBL] [Abstract][Full Text] [Related]
34. Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation. Lee SJ; Song L; Yang MC; Mao CP; Yang B; Yang A; Jeang J; Peng S; Wu TC; Hung CF Vaccine; 2015 Mar; 33(13):1549-55. PubMed ID: 25701675 [TBL] [Abstract][Full Text] [Related]
36. A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern. Ebner S; Hofer S; Nguyen VA; Fürhapter C; Herold M; Fritsch P; Heufler C; Romani N J Immunol; 2002 Jun; 168(12):6199-207. PubMed ID: 12055233 [TBL] [Abstract][Full Text] [Related]
37. Tumor-specific cytokine release by donor T cells induces an effective host anti-tumor response through recruitment of host naive antigen presenting cells. Nagoshi M; Sadanaga N; Joo HG; Goedegebuure PS; Eberlein TJ Int J Cancer; 1999 Jan; 80(2):308-14. PubMed ID: 9935215 [TBL] [Abstract][Full Text] [Related]
38. Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model. Kalaaji AN; Lu J; Markovic SN; Celis E; Pittelkow MR Cytokine; 2010 Mar; 49(3):287-93. PubMed ID: 20060741 [TBL] [Abstract][Full Text] [Related]
39. Targeting tumours with genetically enhanced T lymphocytes. Sadelain M; Rivière I; Brentjens R Nat Rev Cancer; 2003 Jan; 3(1):35-45. PubMed ID: 12509765 [TBL] [Abstract][Full Text] [Related]
40. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Luft T; Luetjens P; Hochrein H; Toy T; Masterman KA; Rizkalla M; Maliszewski C; Shortman K; Cebon J; Maraskovsky E Int Immunol; 2002 Apr; 14(4):367-80. PubMed ID: 11934873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]